2SE Stock Overview
Sequana Medical NV develops and commercializes treatment of fluid overload in liver disease, cancer, and heart failure.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sequana Medical NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.45 |
| 52 Week High | €2.74 |
| 52 Week Low | €1.40 |
| Beta | 0.83 |
| 1 Month Change | -39.58% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -83.52% |
| 5 Year Change | -77.49% |
| Change since IPO | -77.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2SE | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -39.6% | -5.1% | -1.5% |
| 1Y | n/a | -9.0% | 0.9% |
Return vs Industry: Insufficient data to determine how 2SE performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 2SE performed against the German Market.
Price Volatility
| 2SE volatility | |
|---|---|
| 2SE Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2SE's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2SE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 70 | Ian Crosbie | www.sequanamedical.com |
Sequana Medical NV develops and commercializes treatment of fluid overload in liver disease, cancer, and heart failure. The company’s products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally.
Sequana Medical NV Fundamentals Summary
| 2SE fundamental statistics | |
|---|---|
| Market cap | €41.66m |
| Earnings (TTM) | -€32.56m |
| Revenue (TTM) | €712.00k |
56.5x
P/S Ratio-1.2x
P/E RatioIs 2SE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2SE income statement (TTM) | |
|---|---|
| Revenue | €712.00k |
| Cost of Revenue | €164.00k |
| Gross Profit | €548.00k |
| Other Expenses | €33.11m |
| Earnings | -€32.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 23, 2024
| Earnings per share (EPS) | -1.15 |
| Gross Margin | 76.97% |
| Net Profit Margin | -4,573.60% |
| Debt/Equity Ratio | -86.2% |
How did 2SE perform over the long term?
See historical performance and comparison